In metastatic breast cancer, treatment options are largely dependent upon the presence of the oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), in addition to tumour load and location. The gene discussed is ERBB2; the disease is breast cancer.